Literature DB >> 17507072

Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins.

Rodion Gorchakov1, Eugenia Volkova, Nadezda Yun, Olga Petrakova, Nathaniel Seth Linde, Slobodan Paessler, Elena Frolova, Ilya Frolov.   

Abstract

During the last decade, alphaviruses became widely used for expression of heterologous genetic information and development of recombinant vaccines against a variety of human and animal pathogens. In this study, we compared a number of vectors based on the genome of Sindbis (SINV) and Venezuelan equine encephalitis (VEEV) viruses for their ability to express the Rift Valley fever virus (RVFV) envelope glycoprotein Gn and induce a protective immune response against RVFV infection. Our results suggest that (i) application of VEEV-based expression systems appears to be advantageous, when compared to similar systems designed on the basis of the SINV genome. (ii) Alphavirus-specific E3 and E2 proteins and furin-specific cleavage sites can be used for engineering secreted forms of the proteins. (iii) Alphaviruses can be modified for expression of the large fragments of heterologous proteins on the surface of chimeric, infectious viral particles. Thus, alphavirus-based expression systems may have the potential for a broader application beyond their current use as replicons or double-subgenomic vectors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17507072      PMCID: PMC2065871          DOI: 10.1016/j.virol.2007.04.014

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  46 in total

1.  Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins.

Authors:  C S Schmaljohn; M D Parker; W H Ennis; J M Dalrymple; M S Collett; J A Suzich; A L Schmaljohn
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

2.  In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release.

Authors:  P Liljeström; S Lusa; D Huylebroeck; H Garoff
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

3.  Use of bacterial expression cloning to define the amino acid sequences of antigenic determinants on the G2 glycoprotein of Rift Valley fever virus.

Authors:  K Keegan; M S Collett
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

4.  Mutations which alter the level or structure of nsP4 can affect the efficiency of Sindbis virus replication in a host-dependent manner.

Authors:  J A Lemm; R K Durbin; V Stollar; C M Rice
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Complete nucleotide sequence of the M RNA segment of Rift Valley fever virus.

Authors:  M S Collett; A F Purchio; K Keegan; S Frazier; W Hays; D K Anderson; M D Parker; C Schmaljohn; J Schmidt; J M Dalrymple
Journal:  Virology       Date:  1985-07-15       Impact factor: 3.616

6.  Complete nucleotide sequence of the nonstructural protein genes of Semliki Forest virus.

Authors:  K Takkinen
Journal:  Nucleic Acids Res       Date:  1986-07-25       Impact factor: 16.971

7.  Novel coding strategy (ambisense genomic RNA) revealed by sequence analyses of Punta Toro Phlebovirus S RNA.

Authors:  T Ihara; H Akashi; D H Bishop
Journal:  Virology       Date:  1984-07-30       Impact factor: 3.616

8.  A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.

Authors:  P Liljeström; H Garoff
Journal:  Biotechnology (N Y)       Date:  1991-12

9.  Immunoelectron microscopy of Rift Valley fever viral morphogenesis in primary rat hepatocytes.

Authors:  G W Anderson; J F Smith
Journal:  Virology       Date:  1987-11       Impact factor: 3.616

10.  The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83.

Authors:  R M Kinney; B J Johnson; J B Welch; K R Tsuchiya; D W Trent
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

View more
  18 in total

1.  Towards a safe, effective vaccine for Rift Valley fever virus.

Authors:  Desiree Labeaud
Journal:  Future Virol       Date:  2010-11       Impact factor: 1.831

Review 2.  Rift valley fever: recent insights into pathogenesis and prevention.

Authors:  Hani Boshra; Gema Lorenzo; Núria Busquets; Alejandro Brun
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

3.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

4.  Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation.

Authors:  Svetlana Atasheva; Dal Young Kim; Maryna Akhrymuk; David G Morgan; Elena I Frolova; Ilya Frolov
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

5.  Structural and functional elements of the promoter encoded by the 5' untranslated region of the Venezuelan equine encephalitis virus genome.

Authors:  Raghavendran Kulasegaran-Shylini; Svetlana Atasheva; David G Gorenstein; Ilya Frolov
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

Review 6.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 7.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

8.  Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Authors:  Nitin Bhardwaj; Mark T Heise; Ted M Ross
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

9.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

Review 10.  Vaccines for viral hemorrhagic fevers--progress and shortcomings.

Authors:  Darryl Falzarano; Heinz Feldmann
Journal:  Curr Opin Virol       Date:  2013-06-15       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.